RB
VRTX icon

Renasant Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

Renasant Bank’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-532
Closed -$222K – 205
2024
Q1 		$222K Sell
532
-11
-2% -$4.65K 0.16% 166
2023
Q4 		$221K Buy
+543
New +$201K 0.18% 152
2023
Q2 		– Sell
-659
Closed -$208K – 197
2023
Q1 		$208K Sell
659
-310
-32% -$93K 0.16% 180
2022
Q4 		$280K Buy
+969
New +$295K 0.21% 149

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renasant Bank's VRTX Position: Q2 2024 in Review

Renasant Bank sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 532 shares — an estimated $222K sold.

Renasant Bank first reported a position in VRTX in Q4 2022 and held it in 4 quarters. The position peaked at $280K in Q4 2022. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • Renasant Bank reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Renasant Bank sold 532 Vertex Pharmaceuticals shares in Q2 2024, an estimated $222K.
  • Renasant Bank first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Renasant Bank's Vertex Pharmaceuticals position peaked at $280K in Q4 2022.
  • 1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Renasant Bank's 13F filing for Q2 2024, filed 9 Aug 2024.